From: The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
CNV
Early HCC patients, N = 25
Late HCC patients, n = 25
P-value
Gain
3 (12.0%)
4 (16.0%)
1.00
No gain
22 (88.0%)
21 (84.0%)